Orchard Therapeutics plc
ORTXDelisted Jan 24, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001748907
Orchard Therapeutics plc was delisted on Jan 24, 2024; its insiders filed their last Form 4 on Jan 24, 2024; 47 institutions reported holding it in 13F filings for Q4 2023, worth $122.0M in total; no superinvestor held it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 2:10 PM ET
Revenue flow, FY2022
Where the revenue went in FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2022: $150.7M (665.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 20-F |
| Reported | Mar 6, 2023 | Jan 10, 2022 | Jan 11, 2021 | Jan 13, 2020 | – |
| Revenue | $22.7M | $1.68M | $2.60M | $2.51M | $2.08M |
| Cost of revenue | $6.77M | $226.0K | $857.0K | $805.0K | $422.0K |
| Research and development | $93.8M | $87.0M | $93.7M | $117.4M | $205.3M |
| Selling, general and administrative | $49.1M | $54.9M | $65.0M | $57.2M | $31.4M |
| Operating income | -$127.1M | -$140.4M | -$157.0M | -$172.9M | -$235.0M |
| Interest expense | $3.08M | $2.50M | $2.33M | $1.54M | – |
| Income tax | -$2.37M | $828.0K | -$731.0K | -$2.24M | $970.0K |
| Net income | -$150.7M | -$144.6M | -$152.0M | -$163.4M | -$230.5M |
| EPS, basic | $-1.18 | – | – | – | – |
| EPS, diluted | $-1.18 | – | – | – | – |
| Weighted shares, basic | 128.0M | – | – | – | – |
| Weighted shares, diluted | 128.0M | – | – | – | – |
| Margins and growth | |||||
| Operating margin | -561.0% | -8384.1% | -6049.2% | -6879.1% | -11321.3% |
| Net margin | -665.0% | -8631.9% | -5856.6% | -6503.1% | -11102.8% |
| Revenue growth, year over year | +1,252.5% | −35.5% | +3.3% | +21.1% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 20-F |
| Reported | Mar 6, 2023 | Jan 10, 2022 | Jan 11, 2021 | Jan 13, 2020 | – |
| Cash and equivalents | $68.4M | $55.9M | $55.1M | $19.1M | $335.8M |
| Accounts receivable | $8.47M | $1.48M | $878.0K | $1.44M | – |
| Inventory | $3.40M | $2.02M | $665.0K | – | – |
| Total current assets | $168.1M | $275.3M | $223.5M | $349.9M | $355.5M |
| Property, plant and equipment | $8.14M | $4.77M | $4.78M | $7.60M | $5.48M |
| Intangible assets | $3.56M | $4.15M | – | – | – |
| Total assets | $218.9M | $322.4M | $280.9M | $399.3M | $366.0M |
| Accounts payable | $9.32M | $10.0M | $8.82M | $12.0M | $18.1M |
| Short-term debt | $9.43M | $786.0K | $4.86M | – | – |
| Total current liabilities | $60.6M | $42.8M | $51.6M | $55.9M | $47.9M |
| Long-term debt | $23.0M | $32.1M | $20.2M | $24.7M | – |
| Total liabilities | $120.6M | $112.5M | $102.5M | $100.1M | $54.7M |
| Shareholders' equity | $98.3M | $209.9M | $178.4M | $299.2M | $311.3M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 |
| Filing | 10-K | 10-K | 10-K | 10-K | 20-F |
| Reported | Mar 6, 2023 | Jan 10, 2022 | Jan 11, 2021 | Jan 13, 2020 | – |
| Operating cash flow | -$76.0M | -$125.1M | -$126.3M | -$166.1M | -$97.5M |
| Capital expenditures | $6.51M | $2.35M | $2.67M | $4.37M | $4.03M |
| Free cash flow | -$82.5M | -$127.4M | -$128.9M | -$170.5M | -$101.6M |
| Depreciation and amortization | $2.74M | $2.33M | – | – | – |
| Stock-based compensation | $16.0M | $22.5M | $28.0M | $19.4M | $6.77M |
| Investing cash flow | $90.6M | -$32.2M | $157.4M | -$309.4M | -$4.03M |
| Financing cash flow | -$693.0K | $158.1M | $3.94M | $157.5M | $354.9M |
| Net change in cash | $12.5M | $777.0K | $36.1M | -$316.4M | $249.8M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 70.7% | 1345.4% | 1077.5% | 772.9% | 325.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 9, 2023 | 227.6M | +79.7% | SEC |
| Jul 31, 2023 | 227.2M | +79.7% | SEC |
| May 9, 2023 | 184.3M | +46.3% | SEC |
| Mar 10, 2023 | 184.0M | +46.2% | SEC |
| Nov 10, 2022 | 126.7M | +0.9% | SEC |
| Jul 29, 2022 | 126.5M | +0.9% | SEC |
| May 9, 2022 | 125.9M | +1.7% | SEC |
| Mar 15, 2022 | 125.8M | +1.7% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2017, from 13F share counts: 1-for-10 in Q1 2023.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.